Involvement of mitochondria on neuroprotective effect of sphingosine-1-phosphate in cell death in an in vitro model of brain ischemia.

Involvement of mitochondria on neuroprotective effect of sphingosine-1-phosphate in cell death in an in vitro model of brain ischemia.

Neurosci Lett. 2009 Dec 31;

Authors: Agudo-López A, Miguel BG, Fernández I, Martínez AM

Sphingosine-1-phosphate (S1P) has been demonstrated to be an important regulator of cell death and survival. Although it has been suggested that the sphingolipid may act as a neuroprotector in the cell apoptosis induced by traumatic brain injury, the mechanisms involved in this action are unknown. In this study, the relationship between S1P and neuroprotective effect was studied in an in vitro model of ischemia, maintaining SH-SY5Y human neuroblastoma cells under oxygen-glucose deprivation (OGD). When cells were treated with 1muM S1P simultaneously with OGD and recovery, cell viability increases in a dose-response manner. S1P treatment reduces significantly both necrosis and apoptosis cell death. On the other hand, the treatment with specific PKC varepsilon (V1-2), prevents S1P protective effect of OGD/recovery-induced necrosis. Moreover, S1P treatment provokes the translocation of PKC varepsilon to the mitochondria. From these results, it is reasonable to assume that S1P protection from necrosis is mediated by PKC varepsilon. We also studied the action of S1P on mitochondrial inner membrane potential and mitochondrial Ca(2+) levels during ischemia. In this regard, we must point out that S1P treatment reduces the OGD-induced membrane depolarization and also reduces the increase of Ca(2+) in mitochondria during OGD. Results also indicate that mitochondria from OGD treated cells have significantly less ability to resist swelling on Ca(2+) loading than those obtained in presence of oxygen and glucose. Nevertheless, when S1P was added, this resistance increases considerably. These findings suggest that S1P may have a potential role as a neuroprotective agent in brain injury.

PMID: 20045720 [PubMed - as supplied by publisher]

Read the complete post at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=20045720&dopt=Abstract

Posted 5 Jan 2010 4:29 AM by pubmed: neuroblastoma
Filed under:

Seten amet diorl oprta ahsellu miokiste porta.

Bean nonumy hendrit mauris phelus porta. Fusce suscipit varius ui. Fusce feugiat malesada odio. Morbi nunc odio, gravida sit cursusnec, luctus aorem. auris phelus porta ae. Fusce suscipit varius ui. Fusce feug.

Read More

There is nothing quite as devastating as hearing that word - neuroblastoma. In seconds your world is turned upside down and your normal life is but a distant memory. You are thrust into a confusing world full of fear. Your child has cancer.

We know. We have been there. The Neuroblastoma Foundation is here for you.

Welcome to our website. It is a place for you to find answers and ask questions. One of the primary goals of the Neuroblastoma Foundation is to ensure that parents, patients and health care professionals find the information they need to make the best treatment decisions possible for children and adults affected by neuroblastoma. There is a vast amount of information throughout the internet, much of which is encapsulated in medical jargon that is so complex that even many medical professionals have difficulty in interpreting its meaning. We are here to help to decipher this information and to make sure you (and your oncologist) understand exactly what it means to you. From treatment decisions to side effects we have parents and experts that have experienced it all and are willing to distill it for you.